세계 담관암 시장 : 암 유형별, 치료 유형별, 투여 경로별, 유통 채널별, 지역별
Cholangiocarcinoma Market, By Cancer Type, By Therapy Type, By Route of Administration, By Distribution Channel, and By Region
상품코드
:
1378549
리서치사
:
Coherent Market Insights
발행일
:
2023년 10월
페이지 정보
:
영문
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
세계 담관암 시장은 2023년에는 4억 2,320만 달러로 추정되고, 2030년에는 16억 70만 달러에 이를 것으로 예측되며, 예측 기간 중(2023-2030년) 20.9%의 연간 평균 성장률(CAGR)을 나타내는 것으로 예측됩니다.
| 보고 대상 범위 |
보고서 세부정보 |
| 기준년도 |
2022년 |
2023년 시장 규모 |
4억 2,320만 달러 |
| 과거 데이터 |
2018-2021년 |
예측 기간 |
2023-2030년 |
| 예측 기간의 CAGR |
20.90% |
2030년 시장 규모 예측 |
16억 70만 달러 |
그림 1. 세계 담관암 시장 점유율(%), 치료 유형별, 2023년
담관암은 담도암으로도 알려져 있으며 담관에서 발생하는 암의 일종입니다. 담관암은 비교적 드문 암이며 암의 증상이 진행기까지 늦게 나타나는 경우가 많기 때문에 진행된 단계에서 진단될 필요가 있습니다. 담관암의 정확한 원인은 불분명하지만, 담관의 만성 염증, 특정 감염증(간 인플루엔자 기생충 등), 특정 위험 인자(흡연, 다량의 알코올 섭취 등) 등의 요인이 이 암 발병 위험을 높일 것으로 간주됩니다. 진단은 보통 CT 스캔, MRI, 내시경적 역행성 담관 췌관 조영술(ERCP)과 같은 이미지 검사와 암의 존재를 확인하기 위한 조직 생검을 결합합니다. 담관암의 치료법은 암의 병기와 환자의 전신 상태에 따라 다릅니다. 치료에는 수술, 방사선 요법, 화학 요법 및 기타 표적 요법이 있습니다. 담관암의 예후는 진단된 스테이지에 따라 다르며, 예후를 개선하기 위해서는 조기 발견과 개입이 매우 중요합니다.
시장 역학
주요 기업은 연구개발 활동에 임하고 있으며, 이것이 예측기간에 있어서 세계 담관암 시장의 성장을 가속할 것으로 예상됩니다. 예를 들어, 2022년 2월 독일에 본사를 둔 임상 연구 기관인 Institut fur Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest는 "담관암에 대한 수술 후 보조 요법에서 카페시타빈과 병용 또는 카페시타빈이 없는 듀발마브와 트레멜리무맙에 의해 면역요법의 2상 시험"이라는 제목의 임상시험을 시작했습니다. 본 시험은 현재 2상 시험 중이며 2024년 12월까지 완료될 예정입니다.
본 시험의 주요 특징
- 본 보고서는 세계 담관암 시장을 상세하게 분석하여 2022년을 기준년으로 한 예측기간(2023-2030년) 시장 규모 및 복합연간 성장률(CAGR)을 제공합니다.
- 또한 서로 다른 부문에 걸친 잠재적인 수익 기회를 밝히고 이 시장에 대한 매력적인 투자 제안의 행렬을 설명합니다.
- 또한 시장 성장 촉진요인, 억제요인, 기회, 신제품의 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업이 채용하는 경쟁 전략 등에 관한 중요한 고찰도 제공합니다.
- 기업 하이라이트, 제품 포트폴리오, 주요 하이라이트, 성과, 전략 등의 매개변수를 바탕으로 세계 담관암 시장에서 주요 기업을 프로파일링하고 있습니다.
- 이 보고서의 통찰을 통해 마케팅 담당자와 기업 경영진이 향후 제품 출시, 유형 업그레이드, 시장 확대, 마케팅 전술에 대한 정보를 바탕으로 의사 결정을 내릴 수 있습니다.
- 세계 담관암 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 참가자, 재무 분석가 등 이 업계의 다양한 이해관계자를 지원합니다.
- 이해관계자는 세계 담관암 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정이 용이해집니다.
목차
제1장 조사의 목적과 전제
제2장 시장 전망
- 보고서 설명
- 주요 요약
- Coherent Opportunity Map(COM)
제3장 시장 역학, 규제, 동향 분석
- 시장 역학
- 최근 제품 출시 및 승인
- 최근 동향
- 합병, 인수 및 협업
- 규제 시나리오
- 주요 발전
- PEST 분석
- Porter's Five Forces 분석
제4장 세계 담관암 시장 : COVID-19 감염증 영향 분석
- 경제적 영향
- 신형 코로나 바이러스 감염증(COVID-19) 역학
- 수요 및 공급에 미치는 영향
제5장 세계 담관암 시장 : 암 유형별(2018-2030년)
제6장 세계 담관암 시장 : 치료 유형별(2018-2030년)
- 표적 약물요법
- 페미가티닙
- 이보시데닙
- 후치바티닙
- 인피그라티닙
- 화학요법
- 5-플루오로우라실
- 겜시타빈
- 시스플라틴
- 카페시타빈
- 옥살리플라틴
- 면역요법
- 펜브롤리주맙
- 기타(후기 파이프라인 의약품)
- 기타(진통제 등)
제7장 세계 담관암 시장 : 투여 경로별(2018-2030년)
제8장 세계 담관암 시장 : 유통 채널별(2018-2030년)
제9장 세계 담관암 시장 : 지역별(2018-2030년)
- 북미
- 미국
- 캐나다
- 유럽
- 영국
- 독일
- 이탈리아
- 프랑스
- 스페인
- 러시아
- 기타 유럽
- 아시아태평양
- 중국
- 인도
- 일본
- ASEAN
- 호주
- 한국
- 기타 아시아태평양
- 라틴아메리카
- 브라질
- 멕시코
- 아르헨티나
- 기타 라틴아메리카
- 중동
- GCC
- 이스라엘
- 기타 중동
- 아프리카
- 북아프리카
- 중앙 아프리카
- 남아프리카
제10장 경쟁 구도
- 기업 프로파일
- BridgeBio Inc.
- Sanofi
- Eisai Co., Ltd.
- Eli Lilly and Company
- Teva Pharmaceutical Industries Ltd.
- Intas Pharmaceuticals Ltd.
- Fresenius SE & Co. KGaA
- Sun Pharmaceutical Industries Ltd.
- Hikma Pharmaceuticals PLC
- Incyte
- TRISALUS LIFE SCIENCES, INC.
- GENFIT
- Johnson & Johnson Private Limited
- Bliss Biopharmaceutical
- Novartis AG
- LES LABORATOIRES SERVIER
- F.Hoffmann-La Roche Ltd
- Mylan NV(Viatris.Inc)
- AstraZeneca
- Compass Therapeutics, Inc
- Otsuka Holdings Co., Ltd.
- Senhwa Biosciences, Inc.
- 애널리스트의 견해
제11장 섹션
JHS
영문 목차
Global Cholangiocarcinoma market is estimated to be valued at US$ 423.2 Mn in 2023 and is expected to reach US$ 1,600.7 Mn by 2030, exhibiting a Compounded Annual Growth Rate (CAGR) of 20.9% during the forecast period (2023-2030).
| Report Coverage |
Report Details |
| Base Year: |
2022 |
Market Size in 2023: |
US$ 423.2 Mn |
| Historical Data for: |
2018 to 2021 |
Forecast Period: |
2023 - 2030 |
| Forecast Period 2023 to 2030 CAGR: |
20.90% |
2030 Value Projection: |
US$ 1,600.7 Mn |
Figure 1. Global Cholangiocarcinoma Market Share (%), By Therapy Type, 2023
Cholangiocarcinoma, also known as bile duct cancer, is a type of cancer that originates in the bile ducts. Cholangiocarcinoma is a relatively rare cancer which needs to be diagnosed at an advanced stage because the symptoms of the cancer often appears late until the disease is at its well-advanced stage. The exact cause of cholangiocarcinoma is unknown, but it is believed that factors such as chronic inflammation of the bile ducts, certain infections (e.g., with the liver fluke parasite), and certain risk factors (e.g., smoking, heavy alcohol use) may increase the risk of developing this cancer. Diagnosis typically involves a combination of imaging studies, such as CT scans, MRIs, and endoscopic retrograde cholangiopancreatography (ERCP), as well as tissue biopsies to confirm the presence of cancer. Treatment options for cholangiocarcinoma depends on the stage of the cancer and the patient's overall health. The treatments are surgery, radiation therapy, chemotherapy, and other targeted therapies. Prognosis for cholangiocarcinoma varies depending on the stage at which it is diagnosed, and early detection and intervention are crucial for improving outcomes.
Market Dynamics
Key players are engaged in research and development activities which is expected to drive the global cholangiocarcinoma market growth over the forecast period. For instance, in February 2022, Institut fur Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, a Germany-based clinical research institution, initiated a clinical trial titled "A Phase II Study of Immunotherapy with Durvalumab and Tremelimumab in Combination with Capecitabine or Without Capecitabine in Adjuvant Situation for Biliary Tract Cancer". The study is currently in phase 2 which is estimated to get completed by December 2024.
Key features of the study:
- This report provides an in-depth analysis of the global cholangiocarcinoma market and provides market size (US$ Mn) and compound annual growth rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global cholangiocarcinoma market based on the following parameters- company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include BridgeBio Inc., Sanofi, Eisai Co., Ltd., Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Intas Pharmaceuticals Ltd., Fresenius SE & Co. KGaA, Sun Pharmaceutical Industries Ltd., Hikma Pharmaceuticals PLC, Incyte, TRISALUS LIFE SCIENCES, INC., GENFIT, Johnson & Johnson Private Limited, Bliss Biopharmaceutical, Novartis AG, LES LABORATOIRES SERVIER, F. Hoffmann-La Roche Ltd, Mylan N.V. (Viatris.Inc), AstraZeneca, Compass Therapeutics, Inc, Otsuka Holdings Co., Ltd., and Senhwa Biosciences, Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- Global cholangiocarcinoma market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global cholangiocarcinoma market
Detailed Segmentation:
- Global Cholangiocarcinoma Market, By Cancer Type:
- Perihilar
- Distal
- Extrahepatic Cholangiocarcinoma
- Intrahepatic Cholangiocarcinoma
- Global Cholangiocarcinoma Market, By Therapy Type:
- Targeted Drug Therapy
- Pemigatinib
- Ivosidenib
- Futibatinib
- Infigratinib
- Chemotherapy
- 5-fluorouracil
- Gemcitabine
- Cisplatin
- Capecitabine
- Oxaliplatin
- Immunotherapy
- Pembrolizumab
- Others (Late phase pipeline drugs)
- Others (Pain Medications and others)
- By Route of Administration:
- Oral
- Subcutaneous
- Intravenous
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- E-commerce
- By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
- Company Profiles
- BridgeBio Inc.
- Sanofi
- Eisai Co., Ltd.
- Eli Lilly and Company
- Teva Pharmaceutical Industries Ltd.
- Intas Pharmaceuticals Ltd.
- Fresenius SE & Co. KGaA
- Sun Pharmaceutical Industries Ltd.
- Hikma Pharmaceuticals PLC
- Incyte
- TRISALUS LIFE SCIENCES, INC.
- GENFIT
- Johnson & Johnson Private Limited
- Novartis AG
- LES LABORATOIRES SERVIER
- F. Hoffmann-La Roche Ltd
- Mylan N.V. (Viatris.Inc)
- AstraZeneca
- Compass Therapeutics, Inc
- Otsuka Holdings Co., Ltd.
- Senhwa Biosciences, Inc.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Cancer Type
- Market Snippet, By Therapy Type
- Market Snippet, By Route of Administration
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Opportunities
- Recent Product Launches/Approvals
- Recent Trends
- Mergers, Acquisitions, and Collaborations
- Regulatory Scenario
- Key Developments
- PEST Analysis
- PORTER's Analysis
4. Global Cholangiocarcinoma Market - COVID-19 Impact Analysis
- Economic Impact
- COVID-19 Epidemiology
- Impact on Supply and Demand
5. Global Cholangiocarcinoma Market, By Cancer Type, 2018 - 2030, (US$ Mn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
- Extrahepatic Cholangiocarcinoma
- Perihilar
- Distal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
- Segment Trends
- Intrahepatic Cholangiocarcinoma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
- Segment Trends
6. Global Cholangiocarcinoma Market, By Therapy Type, 2018 - 2030, (US$ Mn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
- Targeted Drug Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
- Segment Trends
- Pemigatinib
- Ivosidenib
- Futibatinib
- Infigratinib
- Chemotherapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
- Segment Trends
- 5- fluorouracil
- Gemcitabine
- Cisplatin
- Capecitabine
- Oxaliplatin
- Immunotherapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
- Segment Trends
- Pembrolizumab
- Others (Late phase pipeline drugs)
- Others (Pain Medications and others)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
- Segment Trends
7. Global Cholangiocarcinoma Market, By Route of Administration, 2018 - 2030, (US$ Mn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
- Oral
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
- Subcutaneous
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
- Intravenous
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
8. Global Cholangiocarcinoma Market, By Distribution Channel, 2018 - 2030, (US$ Mn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
- E-commerce
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
9. Global Cholangiocarcinoma Market, By Region, 2018 - 2030, (US$ Mn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2018 -2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2018 -2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018 - 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018 - 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 - 2030, (US$ Mn)
- U.S.
- Canada
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2018 -2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2018 -2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018 - 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018 - 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 - 2030, (US$ Mn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2018 -2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2018 -2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018 - 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018 - 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 - 2030, (US$ Mn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2018 -2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2018 -2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018 - 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018 - 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 - 2030, (US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2018 -2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2018 -2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018 - 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018 - 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 - 2030, (US$ Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2018 -2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2018 -2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018 - 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018 - 2030, (US$ Mn)
- Market Size and Forecast, and By Y-o-Y Growth, By Region, 2018 - 2030, (US$ Mn)
- North Africa
- Central Africa
- South Africa
10. Competitive Landscape
- Company Profiles
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Sanofi
- Eisai Co., Ltd.
- Eli Lilly and Company
- Teva Pharmaceutical Industries Ltd.
- Intas Pharmaceuticals Ltd.
- Fresenius SE & Co. KGaA
- Sun Pharmaceutical Industries Ltd.
- Hikma Pharmaceuticals PLC
- Incyte
- TRISALUS LIFE SCIENCES, INC.
- GENFIT
- Johnson & Johnson Private Limited
- Bliss Biopharmaceutical
- Novartis AG
- LES LABORATOIRES SERVIER
- F.Hoffmann-La Roche Ltd
- Mylan N.V. (Viatris.Inc)
- AstraZeneca
- Compass Therapeutics, Inc
- Otsuka Holdings Co., Ltd.
- Senhwa Biosciences, Inc.
- Analysts' Views
11. Section
- References
- Research Methodology
- About us and Sales Contact
관련자료
